Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Wall Street is incredibly excited about the company’s long-term prospects as it is working on a GLP-1 weight loss pill. Eli Lilly and Company (NYSE:LLY) anticipates having information to share ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... next year we get the fresh phase 3 data for a pill version of Lilly’s GLP-1 treatment, which could be ...

This is due to excessive fat and weight in the body. Nothing seems to work to reduce the weight, which can be very frustrating. Dieting, exercises, workouts, fasting, diet pills, and many other ...